Internal Medicine, Gastroenterology · Merrillville, IN
NPI
1154325421
Since 2005
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
8895 Broadway
Merrillville, IN, 46410
Phone (219) 738-2081
Groups this clinician bills Medicare through
Medicare paid, 2024
$167K
1,969 services
Medicare patients, 2024
1,074
Average age 73
Drug cost, 2024
$988K
3,844 prescriptions
Company payments, 2025
$2,193
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kumar Venkatachalam was code 99213 (office e&m - established), 355 times for 300 patients. In total Kumar Venkatachalam billed 1,969 services in 46 codes, and Medicare paid $167K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-05-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 355 | 300 | $55.58 | $20K |
| 99214 Office E&M - Established | Office | 243 | 203 | $86.03 | $21K |
| 45385 Colonoscopy - Lesion Removal | Facility | 178 | 178 | $168.34 | $30K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 160 | 141 | $11.52 | $1,843 |
| 99232 Hospital E&M - Subsequent | Facility | 132 | 84 | $56.74 | $7,490 |
| 45380 Lower GI Endoscopy - Other | Facility | 100 | 100 | $97.04 | $9,704 |
| 43235 Upper GI Endoscopy | Facility | 96 | 96 | $64.60 | $6,202 |
| 43239 Upper GI Endoscopy | Facility | 86 | 86 | $70.73 | $6,083 |
| 99222 Hospital E&M - Initial | Facility | 79 | 75 | $92.54 | $7,310 |
| 99203 Office E&M - New | Office | 79 | 79 | $73.24 | $5,786 |
| 99221 Hospital E&M - Initial | Facility | 76 | 73 | $58.95 | $4,480 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 60 | 60 | $161.54 | $9,692 |
| 99204 Office E&M - New | Office | 46 | 46 | $109.69 | $5,046 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 46 | 46 | $161.23 | $7,417 |
| 45378 Lower GI Endoscopy - Other | Facility | 45 | 44 | $111.57 | $5,020 |
By year: 2022 $179K for 2,062 services; 2023 $151K for 1,718 services; 2024 $167K for 1,969 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kumar Venkatachalam prescribed most often to Medicare patients was Omeprazole, with 708 prescriptions and refills. In total Kumar Venkatachalam wrote 3,844 Medicare prescriptions that cost $988K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Omeprazole Generic | 708 | 1,609 | 225 | $5,946 |
| Pantoprazole Sodium Generic | 468 | 1,164 | 180 | $6,926 |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 368 | 368 | 356 | $3,713 |
| Dicyclomine Hcl Generic | 302 | 499 | 114 | $4,953 |
| Linzess Linaclotide | 161 | 263 | 49 | $146K |
| Metoclopramide Hcl Generic | 149 | 209 | 44 | $904 |
| Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl | 128 | 128 | 126 | $2,122 |
| Famotidine Generic | 119 | 263 | 46 | $1,270 |
| Ondansetron Hcl Generic | 75 | 75 | 33 | $1,467 |
| Esomeprazole Magnesium Generic | 68 | 162 | 22 | $1,394 |
| Dexlansoprazole Dr Dexlansoprazole | 68 | 150 | 17 | $18K |
| Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl | 67 | 67 | 67 | $881 |
| Sucralfate Generic | 65 | 101 | 25 | $1,458 |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 58 | 62 | 20 | $1,393 |
| Creon Lipase/Protease/Amylase | 56 | 87 | 14 | $172K |
Brand drugs: - claims; generic drugs: 3,275 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kumar Venkatachalam $2,193 ($2,193 in general payments such as food, travel and fees) from 20 companies. The largest payer was Abbvie Inc. with $445.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 27 | $445 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 13 | $263 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 20 | $216 |
| Janssen Biotech, Inc. JNJ | 12 | $178 |
| Madrigal Pharmaceuticals MDGL | 7 | $178 |
| Aimmune Therapeutics, Inc. | 8 | $165 |
| Ardelyx, Inc. ARDX | 5 | $109 |
| Phathom Pharmaceuticals, Inc. PHAT | 5 | $104 |
| Pfizer Inc. PFE | 5 | $92.63 |
| Gilead Sciences, Inc. GILD | 4 | $91.7 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.